Convenience at pricey valuation: Urban Company shares jump 3% but Motilal Oswal remains neutral, here’s why
Motilal Oswal Financial Services initiated coverage on Urban Company shares with a ‘Neutral’ rating, as the domestic brokerage sees a ...
Tag: Motilal
Varun Beverages shares down 22% in one year, but Motilal Oswal sees 35% upside in Pepsi bottler. Here is why
Shares of Varun Beverages have seen a sharp decline recently, falling around 22% in the past one year and 16% ...
L&T shares rise 2% after falling for 4 days: Here’s why Motilal Oswal still remains cautious
Shares of engineering major Larsen & Toubro (L&T) gained a little more than 2% on Thursday, snapping a four-session losing ...
Motilal Oswal Q2 Results: Profit plunges 68% YoY to Rs 362 crore, revenue down 35%
Motilal Oswal Financial Services Ltd (MOFSL) reported 68% year-on-year (YoY) decline in its consolidated net profit at Rs 362 crore. ...
Phoenix Mills shares rally 5% as Motilal Oswal upgrades to ‘Buy’, lifts target price to Rs 2,044
Shares of The Phoenix Mills rallied 5% on Tuesday to an intraday high of Rs 1,597.30 on the BSE after ...
Motilal Oswal Securities bullish on India’s consumer sector; HUL, Marico among top picks
Motilal Oswal Securities has reaffirmed optimism on India’s consumer sector after a steady first quarter. Its top bets are Hindustan ...
HDFC Bank, ICICI Bank poised for strong FY27 earnings, Says Motilal Oswal’s Khemka
India’s banking industry is at an inflection point, with public sector banks (PSBs) reversing a decade-long decline in market share, ...
I am fully desi now, says Motilal Oswal after buying new Mahindra car
Motilal Oswal, the co-founder and CEO of Motilal Oswal Financial Services, has once again drawn attention on social media—not with ...
Buy, Sell or Hold: Motilal Oswal remains neutral on Bajaj Finance; Antique raises Canara Bank’s target price
Brokerages remain selectively optimistic on Indian equities, focusing on sectoral resilience and earnings visibility over the next 12 months.Recent stock ...
Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation play
Motilal Oswal has reiterated a “buy” rating on Glenmark Pharmaceuticals with a raised target price of Rs 2,430, implying a ...
